Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia (CertainT-1)

Next Previous
Search
Trial Profile

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia (CertainT-1)

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CER-1236 (Primary) ; Cyclophosphamide; Fludarabine; Mesna
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms CertainT-1
  • Sponsors CERo Therapeutics

    • Most Recent Events

    • 06 Mar 2025 According to CERo Therapeutics media release, company announced the execution of an agreement with contract research organization (CRO) CellCarta to manage translational assays for the upcoming Phase 1 clinical trial of CER-1236 for Acute Myeloid Leukemia.
    • 08 Mar 2024 According to CERo Therapeutics media release, company plans to file an Investigational New Drug (IND) application in the first half of 2024
    • 14 Feb 2024 According to CERo Therapeutics media release, company anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top